Candesartan Effectiveness study in Pro-B Type Natriuretic Peptides (BNP)

Study identifier:D2452L00012

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A multicenter, non-comparative, phase IV study to evaluate the effect of candesartan based therapy in the percent change of proBNP level after 24 week treatment in the patients with hypertension with left ventricular hypertrophy

Medical condition

hypertension

Phase

Phase 4

Healthy volunteers

No

Study drug

Candesartan, Felodipine

Sex

All

Actual Enrollment

315

Study type

Interventional

Age

18 Years - 75 Years

Date

Study Start Date: 01 Jun 2006
Primary Completion Date: 01 Jun 2008
Study Completion Date: 01 Jun 2008

Study design

Allocation: Non-randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Mar 2012 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria